Trial Information
An Epidemiological, Non-interventional Study to Evaluate Patient Compliance in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
Inclusion Criteria:
- Postmenopausal females with estrogen receptor positive breast cancer that are
currently treated with aromatase inhibitor (AI) medication
- Provision of subject informed consent
Exclusion Criteria:
- If participating in any clinical trial, the subject cannot take part in this study.
Type of Study:
Observational
Study Design:
Time Perspective: Prospective
Outcome Measure:
Evaluate compliance rate, as assessed by investigator, after 12 months from baseline.
Outcome Time Frame:
12 months
Safety Issue:
No
Principal Investigator
Dr Jasna Pesic
Investigator Role:
Principal Investigator
Investigator Affiliation:
M.D.spec of oncology, Institute for oncology Vojvodina, Sremska Kamenica
Authority:
Serbia: Ethics Committee
Study ID:
NIS-ORS-DUM-2010/1
NCT ID:
NCT01208779
Start Date:
January 2011
Completion Date:
March 2012
Related Keywords:
- Hormon Receptor Positive Breast Cancer
- Compliance
- HR+ breast cancer
- epidemiology
- Breast Neoplasms